IART Earnings & Financial Statements
Integra LifeSciences Holdings Corporation
$13.18
-$0.67(-4.87%)
40
Overall
60
Value
18
Tech
42
Quality
Market Cap
$1.02B
Volume
1.11M
52W Range
$8.70 - $20.49
Target Price
$18.82
IART earnings and financial statements: Integra LifeSciences Holdings Corporation's income statement, balance sheet and cash flow statement, annual and quarterly.
IART Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $1.64B | $1.61B | $1.54B | $1.56B | $1.54B |
| Cost of revenue | $803.63M | $728.47M | $656.84M | $587.36M | $597.81M |
| Operating income | -$493.37M | $28.41M | $111.53M | $238.92M | $197.23M |
| EBITDA | -$325.42M | $193.29M | $255.96M | $381.79M | $384.91M |
| Net income | -$516.47M | -$6.94M | $67.74M | $180.55M | $169.07M |
| EPS (diluted) | $-6.74 | $-0.09 | $0.84 | $2.16 | $1.98 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $3.60B | $4.04B | $3.78B | $3.89B | $3.78B |
| Total liabilities | $2.56B | $2.49B | $2.19B | $2.09B | $2.10B |
| Shareholders’ equity | $1.04B | $1.55B | $1.59B | $1.80B | $1.68B |
| Cash and equivalents | $235.05M | $246.38M | $276.40M | $456.66M | $513.45M |
| Long-term debt | $1.89B | $1.25B | $1.65B | $1.46B | $1.48B |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $50.38M | $129.38M | $139.96M | $264.47M | $312.43M |
| Capital expenditure | -$95.64M | -$114.37M | -$66.86M | -$47.09M | -$48.08M |
| Free cash flow | -$45.25M | $15.01M | $73.09M | $217.38M | $264.35M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IART | $13.18 | -4.9% | 1.11M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Integra LifeSciences Holdings Corporation Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW